Bellerophon Therapeutics (NASDAQ: BLPH) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Bellerophon Therapeutics to related businesses based on the strength of its risk, institutional ownership, profitability, dividends, analyst recommendations, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Bellerophon Therapeutics and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bellerophon Therapeutics 0 0 2 0 3.00
Bellerophon Therapeutics Competitors 846 3196 11590 230 2.71

Bellerophon Therapeutics currently has a consensus target price of $4.75, indicating a potential upside of 156.76%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.77%. Given Bellerophon Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Bellerophon Therapeutics is more favorable than its competitors.

Risk and Volatility

Bellerophon Therapeutics has a beta of -0.37, meaning that its stock price is 137% less volatile than the S&P 500. Comparatively, Bellerophon Therapeutics’ competitors have a beta of 6.19, meaning that their average stock price is 519% more volatile than the S&P 500.

Institutional & Insider Ownership

43.6% of Bellerophon Therapeutics shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 60.4% of Bellerophon Therapeutics shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Bellerophon Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bellerophon Therapeutics N/A -276.82% -78.56%
Bellerophon Therapeutics Competitors -5,306.52% -432.90% -39.18%

Valuation & Earnings

This table compares Bellerophon Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bellerophon Therapeutics N/A -$23.81 million -1.41
Bellerophon Therapeutics Competitors $284.28 million $34.29 million 136.22

Bellerophon Therapeutics’ competitors have higher revenue and earnings than Bellerophon Therapeutics. Bellerophon Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company’s second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company’s BCM is in PRESERVATION I clinical trial.

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.